Evidence map›Paper›PMID 22692023›Full record

Trial reportEuropean journal of clinical nutrition2012

Milk containing probiotic Lactobacillus rhamnosus GG and respiratory illness in children: a randomized, double-blind, placebo-controlled trial.

M Kumpu, R A Kekkonen, H Kautiainen, S Järvenpää, A Kristo, P Huovinen, A Pitkäranta, R Korpela, K Hatakka

Registry-linked trialAbstract readMulticenter StudyRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in European journal of clinical nutrition, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05378022 (Application of LiveSpo Navax in Treatment of Acute Respiratory Disease in Children Infected With Influenza Virus), which is not on this map. Cited by 46 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed, 7 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05378022 nacompletednot on this mapstarted 2020, after this paper: background citation

Application of LiveSpo Navax in Treatment of Acute Respiratory Disease in Children Infected With Influenza Virus

TypeinterventionalSponsorNational Children's Hospital, VietnamRan2020 to 2022Enrolled70ConditionsAcute Respiratory Tract InfectionsArmsLiveSpo Navax, 0.9% NaCl physiological saline
3 · Its place in the literature

Who cites it

46 citing papers in PubMed, 7 syntheses or guidelines pooled it.

  1. Probiotics for preventing acute upper respiratory tract infections.The Cochrane database of systematic reviews · 2022
    Pooled it
  2. Pooled it
  3. Probiotics for preventing acute otitis media in children.The Cochrane database of systematic reviews · 2019
    Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Specific probiotics and virological findings in symptomatic conscripts attending military service in Finland.Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology · 2014
    Trial
  17. Trial
  18. Nasal delivery ofMicrobiology spectrum · 2026
    Article
  19. Article
  20. Role ofPreventive nutrition and food science · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

M KumpuValio Ltd, Helsinki, Finland.
R A Kekkonen
H Kautiainen
S Järvenpää
A Kristo
P Huovinen
A Pitkäranta
R Korpela
K Hatakka

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

objectivesTo determine whether long-term daily consumption of milk containing probiotic Lactobacillus rhamnosus GG (GG) decreases respiratory illness in children. SUBJECTS/

methodsA randomized, double-blind, placebo-controlled trial was conducted with 523 children aged 2-6 years attending day care centers in Finland. Subjects received either normal milk or the same milk with GG on three daily meals for 28 weeks. Daily recording of children' symptoms was done by parents. Primary outcome data from 501 subjects were available for analysis, and data from 128 subjects were analyzed as completed cases in terms of recovery of GG in fecal samples.

resultsNumber of days with at least one respiratory symptom in all subjects was 5.03/month (95% confidence interval (CI): 4.92-5.15) in the GG group and 5.17/month (95% CI: 5.05-5.29) in the placebo group incidence rate ratio (IRR) 0.97; 95% CI: 0.94-1.00; P=0.098). In the completed cases, the figures were 4.71 days/month (95% CI: 4.52-4.90) in the GG group and 5.67 days/month (95% CI: 5.40-5.94) in the placebo group (IRR 0.83; 95% CI: 0.78-0.88; P<0.001).

conclusionsConsumption of GG reduced the occurrence of respiratory illness in children attending day care centers in the completed cases subgroup, but not in the total population. Thus, future clinical trials are warranted to clarify the association between fecal recovery of a probiotic and the symptom prevalence.

Indexed as

Lacticaseibacillus rhamnosusAnimalsChildChild, PreschoolChi-Square DistributionDouble-Blind MethodFecesFinlandHumansMilkProbioticsRespiratory Tract Infections

Identifiers

PMID22692023

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.